Robust IMPT modestly reduced organ-at-risk dose in five-fraction prostate proton therapy
SFUD and robust IMPT maintained target coverage under uncertainty, while IMPT modestly reduced rectal and bladder dose.
Tag
prostate
Prostate reirradiation strategies remain heterogeneous despite encouraging prospective outcomes
Prospective prostate reirradiation studies reported generally acceptable toxicity, but target volumes, dose schedules and organ constraints varied substantially.
SPPORT intensification did not worsen long-term quality of life
Short-term androgen deprivation impaired early sexual and hormonal quality of life, but treatment-arm differences were not clinically significant at five years.
Upright carbon ion plans matched supine dosimetry for prostate cancer
Upright carbon ion treatment plans achieved target coverage, organ sparing and simulated robustness comparable with conventional supine plans.
MRI-guided prostate SBRT reduced low-dose exposure to sexual-function structures
MRI-guided SBRT with 2-mm margins reduced low- and intermediate-dose exposure of neurovascular bundles and pudendal arteries versus CT-guided treatment.
DEGRO supports ultrahypofractionation for localized prostate cancer but flags higher late urinary toxicity
DEGRO supports ultrahypofractionation for low- to intermediate-risk prostate cancer, with comparable control but increased late genitourinary toxicity in selected patients.
Five-fraction prostate and pelvic nodal SBRT showed low late toxicity
After prostate and pelvic nodal SBRT, no grade ≥3 late GU or GI toxicity occurred among 101 patients with high-risk disease.
Pelvis-inclusive SBRT reduced acute gastrointestinal toxicity in high-risk prostate cancer
Once-weekly prostate-and-pelvis SBRT reduced acute gastrointestinal toxicity versus conventional IMRT without significantly increasing genitourinary toxicity.
CT-guided online adaptation improved prostate SBRT dosimetry
CT-guided online adaptive prostate SBRT was feasible, with adapted plans selected in 95% of fractions and dosimetric improvements in 85%.
MIM software accelerated sarcopenia screening during prostate radiotherapy planning
MIM-based skeletal muscle index measurement matched ImageJ while reducing processing time from 10 to 3.5 minutes.
High-dose-rate brachytherapy monotherapy achieved durable prostate cancer control
High-dose-rate brachytherapy monotherapy achieved 86% biochemical control at median 13-year follow-up in localized prostate cancer.
Same-day hyaluronic acid spacer reduced rectal dose in prostate brachytherapy
Same-day hyaluronic acid rectal spacer placement reduced rectal dose while preserving ultrasound-based prostate brachytherapy planning.
Magnetic resonance-only simulation supported prostate magnetic resonance-guided stereotactic body radiotherapy
Magnetic resonance-only prostate simulation achieved 96.80% local gamma agreement using synthetic computed tomography for dose calculation.
Rectal air did not compromise prostate online adaptive radiotherapy robustness
Rectal air or air-filled balloons did not cause clinically relevant dose increases when posterior tissue shifts stayed within 5 millimetres.
Daily adaptive prostate stereotactic body radiotherapy improved target coverage
Daily cone-beam computed tomography-based adaptation improved prostate stereotactic body radiotherapy target coverage, but organ-at-risk dose benefits were inconsistent.